Founded in 1998, the Sinai Center for Thrombosis Research (SCTR) is primarily devoted to translational research related to thrombosis in patients undergoing interventional cardiovascular procedures.
As pioneers and world leaders in the field of antithrombotic therapy, Paul A. Gurbel, M.D. and his team have amassed one of the largest bodies of data related to platelet function in patients undergoing catheter-based coronary revascularization procedures. Other investigations have studied patients with heart attacks, the leading cause of cardiac death.
Major Research Interests:
Thrombosis and vascular biology
- Innovations in catheter-based treatment of vascular disease
- Treatment of myocardial infarction
- Platelet activation in heart disease
- Fibrinolytic therapy/platelet activation
- Antiplatelet therapy/mechanisms and clinical effects of drug resistance
- Novel pathways of platelet-platelet and platelet-leukocyte interactions
SCTR is equipped with a state-of-the art laboratory housed in an area of the hospital directly adjacent to the cardiac catheterization laboratory, the largest in the region. These resources and unique location grant the Center the capacity to conduct the most intricate investigations of platelet physiology and coagulation. Additionally, SCTR contains an in-patient clinical research center, where serial pharmacodynamic and pharmacokinetic studies are conducted.
- Clinical trials and outcome studies
- Antithrombotic drug development
- Pharmacokinetic, genetic, and platelet function testing
- Biomarker core lab (CLIA certified lab)
- Consulting and protocol development
Original investigations conducted by SCTR have been presented nationally and internationally in the most prestigious venues, including the American Heart Association and American College of Cardiology Scientific Sessions, the European Congress of Cardiology, and the Congress of the International Society on Thrombosis and Haemostasis. The Center is particularly recognized for its landmark investigations of resistance to antiplatelet drug therapy and its clinical implications. This groundbreaking work has led to patents in the area of translational research. SCTR's discoveries have elucidated how drugs affect coronary thrombosis and also how selected patients remain at risk despite receiving antiplatelet therapy, an area of investigation termed, "personalized antiplatelet therapy."